GLPG1690: Phase I data

A 2-part, double-blind, placebo-controlled, Belgian Phase I trial in 40 healthy male volunteers ages 18-50 showed that single and multiple ascending doses of oral GLPG1690 were well tolerated. Subjects received single doses of 20-1,500 mg GLPG1690 or 300-1,000 mg GLPG1690 once daily for 14 days. Galapagos plans to explore a Phase II trial design of GLPG1690 to treat pulmonary diseases, but declined to disclose a timeline. ...